Sep 10, 2018   SOURCE: PR NewsWire

Global Metastatic Bone Disease Market 2017-2023

DUBLIN, Sept. 10, 2018 /PRNewswire/ --

The "Global Metastatic Bone Disease Market - by Treatment, Origin of Metastasis, End User, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)" report has been added to ResearchAndMarkets.com's offering.

The Global Metastatic Bone Disease Market was worth 12.45 Billion USD in 2017 and it is estimated to grow to 19.86 Billion USD by 2023 with a CAGR of 8.09% between 2017 and 2023.

The North America is expected to have largest Global Metastatic Bone Disease Market mainly due to the developing regions such as U.S., Canada, and others. The Asia Pacific is expected to be the fastest growing region over the forecast period.

Drivers Vs. Constraints

    --  The increased prevalence of cancer and investment on the drug discovery
        and development are the main reasons which drives growth of Global
        Metastatic Bone Disease Market.
    --  The increasing use of the generic medicine is the factor which restrains
        this market growth.

Industry Structure and Updates

Over 600,000 of bone metastasis are diagnosed in the U.S. every year according to the University of Texas South-western Medical Center, Dallas.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Market Overview

4. Market Dynamics

5. Global Metastatic Bone Disease Market Segmentation, Forecasts and Trends - by Treatment
5.1. Medication
5.1.1. Chemotherapy
5.1.2. Hormone Therapy
5.1.3. Bisphosphonates
5.1.4. Opiate Therapy
5.1.5. Immunotherapy
5.2. Radiation Therapy
5.3. Surgical Intervention
5.4. Tumor Ablation Therapy

6. Global Metastatic Bone Disease Market Segmentation, Forecasts and Trends - by Origin of Metastasis
6.1. Breast
6.2. Lung
6.3. Thyroid
6.4. Kidney
6.5. Prostate
6.6. Others

7. Global Metastatic Bone Disease Market Segmentation, Forecasts and Trends - by End User
7.1. Hospitals
7.2. Specialty Clinics
7.3. Ambulatory Surgical Centers

8. Global Metastatic Bone Disease Market Segmentation, Forecasts and Trends - by Region

9. Company Market Share Analysis

10. Company Profiles 

    --  Amgen, Inc.
    --  Merck & Co., Inc.
    --  F. Hoffmann-La Roche Ltd.
    --  Novartis AG
    --  Eli Lilly and Company
    --  Bayer AG
    --  Fresenius Kabi AG
    --  BTG plc
    --  Boston Scientific Corporatio
    --  Medtronic
    --  Ethicon, Inc.
    --  C. R. Bard, Inc
    --  Apollo Endosurgery
    --  EndoEvolution, LLC,
    --  LSI Solutions, Inc
    --  SuturTek, Inc

For more information about this reportvisit

https://www.researchandmarkets.com/research/ldsjt7/global_metastatic?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content to download multimedia:http://www.prnewswire.com/news-releases/global-metastatic-bone-disease-market-2017-2023-300709522.html

SOURCE Research and Markets